Bradley C. Faris is a partner based in the Chicago office of Latham & Watkins and a member of the firm's Corporate Department and Mergers and Acquisitions Group. His practice focuses on public and private mergers and acquisitions, with a particular interest in friendly and unsolicited tender offers and proxy contests, takeover defense counseling and advising independent directors in conflict of interest transactions. Mr. Faris has represented both buyers and sellers in mergers and acquisitions, including representing Koch Industries, Inc. in its $22 billion tender offer for Georgia-Pacific Corporation; the Special Committee of the Board of Directors of CBOT Holdings, Inc. in its $12 billion merger with Chicago Mercantile Exchange Holdings Inc.; Eli Lilly and Company in its $6.5 billion tender offer for ImClone Systems Inc.; Ericsson in its $2.1 billion tender offer for Redback Networks Inc.; CCC Information Services Group Inc. in its $500 million merger with affiliates of Investcorp; First Health Group Corp. in its $1.9 billion stock-for-stock merger with Coventry Health Care, Inc. and Axcan Pharma Inc. in an unsolicited tender offer and proxy context for Salix Pharmaceuticals, Inc. Mr. Faris also has represented financial advisors in M&A transactions, including Credit Suisse, Goldman Sachs and UBS Investment Bank.
Mr. Faris recently co-authored “The Resurgent Rights Plan: Recent Poison Pill Developments and Trends” and “Special Negotiating Committees: If, When, Who and How—A Guide for the General Counsel.” Mr. Faris also co-authored an article titled “Second-Generation Shareholder Bylaws: Post-Quickturn Alternatives.”
Mr. Faris is a member of the Chicago Bar Association and the Illinois Bar Association. He is admitted to practice in the state of Illinois.